These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 12492017)

  • 1. BMS-232632, a new protease inhibitor, is taken once daily.
    Gaylord G
    Posit Living; 2000 Jul; 9(6):22. PubMed ID: 12492017
    [No Abstract]   [Full Text] [Related]  

  • 2. Boosted Reyataz: 48-week results.
    Huff B
    GMHC Treat Issues; 2004; 18(1-2):15. PubMed ID: 15119279
    [No Abstract]   [Full Text] [Related]  

  • 3. [New data on atazanavir/r]].
    MMW Fortschr Med; 2005 Apr; 147 Spec No 1():81-3. PubMed ID: 16385887
    [No Abstract]   [Full Text] [Related]  

  • 4. [Simplified HIV therapy. Atazanavir: the first protease inhibitor with once daily administration].
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():14-6. PubMed ID: 15373035
    [No Abstract]   [Full Text] [Related]  

  • 5. Reyataz dosing options discussed. Excerpts from the FDA atazanavir hearing.
    Huff B
    GMHC Treat Issues; 2003 Jun; 17(6):8-11. PubMed ID: 12913962
    [No Abstract]   [Full Text] [Related]  

  • 6. Drug interactions. Kaletra and atazanavir.
    TreatmentUpdate; 2006; 18(3):7-8. PubMed ID: 17211919
    [No Abstract]   [Full Text] [Related]  

  • 7. CASTLE analysis finds no benefit for once daily dosing.
    Proj Inf Perspect; 2008 Dec; (47):4. PubMed ID: 19226675
    [No Abstract]   [Full Text] [Related]  

  • 8. [New treatment options for HIV-infected patients].
    Wehr A
    Dtsch Med Wochenschr; 2004 May; 129(19):1093. PubMed ID: 15174468
    [No Abstract]   [Full Text] [Related]  

  • 9. Anti-HIV agents. Atazanavir and saquinavir.
    TreatmentUpdate; 2004; 16(3):9-10. PubMed ID: 17219610
    [No Abstract]   [Full Text] [Related]  

  • 10. Anti-HIV agents. Atazanavir and raltegravir--an interesting combination.
    TreatmentUpdate; 2009; 21(3):3-4. PubMed ID: 19623725
    [No Abstract]   [Full Text] [Related]  

  • 11. New protease inhibitor atazanavir (Reyataz) approved.
    AIDS Treat News; 2003 Jun; (392):3. PubMed ID: 12913956
    [No Abstract]   [Full Text] [Related]  

  • 12. Drug profile: atazanavir (Reyataz, ATV).
    Pham PA
    Hopkins HIV Rep; 2003 Jul; 15(4):4-5. PubMed ID: 14696562
    [No Abstract]   [Full Text] [Related]  

  • 13. [Interview with Professor Jürgen Rockstroh, director of the Bonn University Clinic. Atazanavir in general practice].
    Rockstroh J
    MMW Fortschr Med; 2004 Apr; 146 Spec No 1():18-9. PubMed ID: 15373037
    [No Abstract]   [Full Text] [Related]  

  • 14. Atazanavir background documents available.
    AIDS Treat News; 2003 May; (391):3. PubMed ID: 12866495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress toward a once daily regimen. (HA)ART--the art of antiretroviral therapy].
    MMW Fortschr Med; 2001 Apr; 143 Suppl 1():78-9. PubMed ID: 11373790
    [No Abstract]   [Full Text] [Related]  

  • 16. FDA notifications. Alternative dosing regimen for atazanavir is approved.
    AIDS Alert; 2008 Nov; 23(11):129-30. PubMed ID: 19048649
    [No Abstract]   [Full Text] [Related]  

  • 17. [Highly effective drug without modifying the lipid profile. Atazanavir, the protease inhibitor for "once daily" administration].
    MMW Fortschr Med; 2003 Apr; 145 Spec No 1():14-5. PubMed ID: 15011577
    [No Abstract]   [Full Text] [Related]  

  • 18. A king in the CASTLE? Optimum initial HIV protease inhibitor.
    Torti C; Frank I
    Lancet; 2008 Aug; 372(9639):604-6. PubMed ID: 18722849
    [No Abstract]   [Full Text] [Related]  

  • 19. Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.
    Gatell J; Salmon-Ceron D; Lazzarin A; Van Wijngaerden E; Antunes F; Leen C; Horban A; Wirtz V; Odeshoo L; Van den Dungen M; Gruber C; Ledesma E;
    Clin Infect Dis; 2007 Jun; 44(11):1484-92. PubMed ID: 17479947
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-HIV agents. Atazanavir as a booster for protease inhibitors.
    TreatmentUpdate; 2003; 15(4):1-2. PubMed ID: 17216850
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.